01/20/2019

HIV/AIDS Vaccine Discovery Is Not Far

By Live Dr - Sun Dec 11, 1:07 am

As our feature story this week makes clear, the fight against HIV/AIDS is far from over. But researchers from the University of Washington and the Fred Hutchinson Cancer Research Center have made significant progress developing a vaccine for the virus, and the Gates Foundation has spent more than $2.2 billion funding the science.
HIV / AIDS Vaccine

HIV / AIDS Vaccine

The most recent positive development comes courtesy of Dr. Shiu-Lok Hu. A professor of pharmaceutics at the UW School of Pharmacy, Hu is the creator of the “prime-boost” immunization method. The “prime-boost” method was used in the famed RV144 trial in Thailand in 2009, in which the vaccine combination prevented upward of 32 percent of new infections.
Here’s what “Prime-boost” means in plain English, courtesy of UW:
This method uses two vaccine components — a relatively harmless virus that delivers HIV proteins and primes the immune system, followed by booster shots of the HIV proteins themselves. This one-two punch approach activates both antibody and cell-mediated immune responses…
…The goal of [Hu’s] study is to build upon the success of the prime-boost strategy and to explore vaccine designs that may generate protective antibodies targeting the part of the virus it uses to bind to immune cells — the part widely considered the Achilles heel of the virus. Hu’s lab has previously shown that the removal of a specific glycan molecule on the envelope protein used by the virus to enter the host cell resulted in an enhanced ability of the mutant protein to induce neutralizing antibodies.
Earlier this week, Hu was awarded a $6.7 million grant from the Gates Foundation, allowing him to join their Collaboration for AIDS Vaccine Discovery. Launched in 2006, the Collaboration is a group effort that has included more than 500 investigators from 94 institutions in 19 countries.
Despite the specificity of their name, the Fred Hutchinson Cancer Research Center also specializes in HIV/AIDS research. The Hutch leads the HIV vaccine trials network (HVTN), a global network currently testing 12 different prospective vaccines.
Dr. Jim Kublin, executive director of the HVTN, says some “very exciting” research will be published in the coming weeks in the New England Journal of Medicine regarding “correlates” for HIV protection. In layman’s terms, a correlate is like a signpost that points scientists toward what works about a particular vaccine and why.
“Evidence that there’s a biological marker for that potential protection is a major milestone for the field,” Kublin says. “We can now use that as one among several benchmarks to measure other vaccines, and develop them to make them more effective. That’s the biggest news out of the field in the past couple months.”
The study was conducted in Thailand (a continuation of the RV144 Trials), and the statistical analysis done at the Hutch. Kublin says his group is “conducting more clinical trials [for HIV vaccines] than any other group in the world right now.”
Another highlight is research by doctors Julie Overbaugh and Catherine Blish. They found that two mutations in one strain of HIV-1 could make the virus vulnerable to attack by the body’s immune system. According to the Hutch, “these findings could form the foundation for new vaccines that could help the body to fight off HIV.”
The bad news is that, despite all the progress, about 2.3 million people still become newly infected with HIV every year. (Our feature this week focused on whether a form of birth control popular in Africa is contributing to the spread of HIV.) The good news is that anti-retroviral drugs and other forms of treatment have turned a disease that used to be 100 percent fatal into one for which average life expectancy exceeds 20 years. That’s progress

As our feature story this week makes clear, the fight against HIV/AIDS is far from over. But researchers from the University of Washington and the Fred Hutchinson Cancer Research Center have made significant progress developing a vaccine for the virus, and the Gates Foundation has spent more than $2.2 billion funding the science.The most recent positive development comes courtesy of Dr. Shiu-Lok Hu. A professor of pharmaceutics at the UW School of Pharmacy, Hu is the creator of the “prime-boost” immunization method. The “prime-boost” method was used in the famed RV144 trial in Thailand in 2009, in which the vaccine combination prevented upward of 32 percent of new infections.
Here’s what “Prime-boost” means in plain English, courtesy of UW:
This method uses two vaccine components — a relatively harmless virus that delivers HIV proteins and primes the immune system, followed by booster shots of the HIV proteins themselves. This one-two punch approach activates both antibody and cell-mediated immune responses……The goal of [Hu’s] study is to build upon the success of the prime-boost strategy and to explore vaccine designs that may generate protective antibodies targeting the part of the virus it uses to bind to immune cells — the part widely considered the Achilles heel of the virus. Hu’s lab has previously shown that the removal of a specific glycan molecule on the envelope protein used by the virus to enter the host cell resulted in an enhanced ability of the mutant protein to induce neutralizing antibodies.
Earlier this week, Hu was awarded a $6.7 million grant from the Gates Foundation, allowing him to join their Collaboration for AIDS Vaccine Discovery. Launched in 2006, the Collaboration is a group effort that has included more than 500 investigators from 94 institutions in 19 countries.Despite the specificity of their name, the Fred Hutchinson Cancer Research Center also specializes in HIV/AIDS research. The Hutch leads the HIV vaccine trials network (HVTN), a global network currently testing 12 different prospective vaccines.
Dr. Jim Kublin, executive director of the HVTN, says some “very exciting” research will be published in the coming weeks in the New England Journal of Medicine regarding “correlates” for HIV protection. In layman’s terms, a correlate is like a signpost that points scientists toward what works about a particular vaccine and why.
“Evidence that there’s a biological marker for that potential protection is a major milestone for the field,” Kublin says. “We can now use that as one among several benchmarks to measure other vaccines, and develop them to make them more effective. That’s the biggest news out of the field in the past couple months.”
The study was conducted in Thailand (a continuation of the RV144 Trials), and the statistical analysis done at the Hutch. Kublin says his group is “conducting more clinical trials [for HIV vaccines] than any other group in the world right now.”
Another highlight is research by doctors Julie Overbaugh and Catherine Blish. They found that two mutations in one strain of HIV-1 could make the virus vulnerable to attack by the body’s immune system. According to the Hutch, “these findings could form the foundation for new vaccines that could help the body to fight off HIV.”
The bad news is that, despite all the progress, about 2.3 million people still become newly infected with HIV every year. (Our feature this week focused on whether a form of birth control popular in Africa is contributing to the spread of HIV.) The good news is that anti-retroviral drugs and other forms of treatment have turned a disease that used to be 100 percent fatal into one for which average life expectancy exceeds 20 years. That’s progress

157 Comments

Comments 151 - 157 of 157First« PrevNext »Last
  1. Howdy just wanted to give you a quick heads up.
    The words in your article seem to be running off the screen in Chrome.
    I’m not sure if this is a format issue or something
    to do with web browser compatibility but I figured I’d post to let you know.
    The design and style look great though! Hope you get the problem fixed soon. Kudos

    Barcelona fotballdrakter 2018

  2. There’s definately a great deal to know about this subject.

    I like all the points you’ve made.

    maglia Athletic Bilbao poco prezzo

  3. I precisely wished to thank you so much yet again. I’m not certain what I might have created without the entire creative ideas documented by you relating to my industry. It was before a real fearsome situation in my circumstances, however , seeing a professional approach you resolved the issue made me to cry with happiness. I’m just thankful for the help as well as believe you are aware of a great job your are carrying out training others through the use of your web site. I’m certain you’ve never come across all of us.

  4. I in addition to my buddies have been viewing the great recommendations from your web blog then unexpectedly came up with an awful feeling I never expressed respect to the blog owner for those tips. Most of the guys appeared to be for that reason thrilled to study all of them and have now truly been having fun with these things. Appreciation for really being very accommodating and also for finding certain remarkable topics millions of individuals are really wanting to be informed on. Our own sincere apologies for not expressing gratitude to you earlier.

  5. you are in point of fact a just right webmaster.

  6. I precisely desired to appreciate you once again. I am not sure the things that I would’ve achieved without those ways contributed by you directly on my industry. It had been a very frightful crisis in my opinion, but taking note of a specialised form you managed that forced me to cry for joy. I will be happy for your work and thus expect you recognize what a powerful job you have been accomplishing teaching many people with the aid of your webblog. I’m certain you’ve never come across any of us.

  7. it looks good. I ave bookmarked it in my google bookmarks.

Comments 151 - 157 of 157First« PrevNext »Last

Leave a Reply